---
layout: default
title: Alogliptin
parent: 僅模型預測 (L5)
nav_order: 23
evidence_level: L5
indication_count: 0
---

# Alogliptin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ALOGLIPTIN: Drug Repurposing Evaluation Report

## One-Sentence Summary

Alogliptin (DB06203) is a DPP-4 inhibitor primarily used for the treatment of type 2 diabetes mellitus. Currently, the TxGNN model has **no predicted new indications** for this drug, and there are **no clinical trials** or **publications** associated with a repurposing direction. This candidate requires further data collection before evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Type 2 diabetes mellitus (DPP-4 inhibitor; no Taiwan-approved indication on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions or supporting studies available) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any predicted new indications for alogliptin. Without a repurposing hypothesis, a mechanistic rationale cannot be evaluated at this time.

Based on publicly available knowledge, alogliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that works by preventing the degradation of incretin hormones (GLP-1 and GIP), thereby increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. It is approved in multiple markets (including the US, EU, and Japan) for the management of type 2 diabetes mellitus, often in combination with metformin or pioglitazone.

> **Note:** The Evidence Pack lists the mechanism of action as unavailable. The above description is based on established pharmacological literature for alogliptin. Once DrugBank API data is retrieved (see Data Gap DG002), this section should be updated with the authoritative MOA description.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for any repurposing indication.

*(This section will be populated once TxGNN generates predicted indications and evidence is collected.)*

---

## Literature Evidence

Currently no related literature available for any repurposing indication.

*(This section will be populated once TxGNN generates predicted indications and evidence is collected.)*

---

## Taiwan Market Information

Alogliptin currently holds **no marketing authorizations** in Taiwan (TFDA). No licenses were found in the regulatory query performed on 2026-03-29.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> **Note:** TFDA package insert data and DrugBank safety warnings were not available at the time of this report. Key warnings, contraindications, and drug-drug interactions remain to be collected (see Data Gaps below).

---

## Data Gaps Requiring Resolution

The following critical data gaps were identified during evidence pack assembly:

| Gap ID | Category | Item | Severity | Impact | Remediation |
|--------|----------|------|----------|--------|-------------|
| DG001 | Drug Level | TFDA Package Insert Warnings / Contraindications | **Blocking** | Cannot enter S1 safety preliminary assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | **High** | Affects mechanistic relevance analysis | Query DrugBank API |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There are no TxGNN-predicted new indications for alogliptin at this time. Additionally, two critical data gaps (TFDA package insert and MOA) remain unresolved — one of which (DG001) is classified as **Blocking** and prevents safety assessment from proceeding.

**To proceed, the following is needed:**
- **Run or re-run TxGNN prediction** for alogliptin to determine if any new indications are generated
- **Resolve DG001 (Blocking):** Obtain TFDA package insert warnings and contraindications, or source equivalent safety data from another regulatory authority (e.g., FDA, EMA, PMDA) given alogliptin is not marketed in Taiwan
- **Resolve DG002 (High):** Retrieve detailed mechanism of action from DrugBank API
- **Reassess market availability:** Since alogliptin is not marketed in Taiwan, consider whether the drug can be sourced through special import channels or clinical trial supply if a repurposing indication is identified
- **Re-evaluate** once the above data is collected and TxGNN predictions are available
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

